SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are facing significant volatility as investors react to a double earnings miss, with sentiment split between those viewing the pullback as a buying opportunity and critics concerned about the company's heavy reliance on crypto market cycles. While community debate remains heated regarding the stock's long-term valuation and historical controversies, many are closely watching management's pivot toward prediction markets and subscriber growth for signs of a turnaround.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant retail and institutional attention ahead of its upcoming earnings report, with the community actively debating whether the stock will trigger a short squeeze or face continued downward pressure similar to other fintech sector peers. Traders are fixated on key metrics like revenue growth, member expansion, and potential guidance, while the community remains polarized between long-term "bulls" expecting a breakout and skeptical "bears" highlighting the stock's recent volatility and valuation concerns.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is experiencing significant market attention as strong AI-driven storage demand and record-breaking financial performance confirm a structural boom in the memory and storage sector. The community is actively debating the sustainability of this parabolic rally, with many investors weighing aggressive momentum plays against concerns over stretched valuations and historical sector cycles.

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Quantum BioPharma Ltd

Quantum BioPharma is trending as investors monitor high-stakes developments in its $700 million federal market manipulation lawsuit against major banks, alongside ongoing speculation regarding the clinical progress of its Lucid-MS program. The community remains deeply divided, with some traders optimistic about a potential short squeeze fueled by media coverage and legal catalysts, while others warn of historical dilution, lack of revenue, and concerns over management's capital allocation strategy.

HashPack is the leading retail wallet on Hedera Hashgraph with a fantastic user experience for defi, NFTs and dApps. The wallet is non-custodial, audited and features free email account creation as well as seed phrase based account creation. HashPack is integrated with every major dApp in the Hedera Hashgraph ecosystem and is deeply involved in the retail and developer communities.

HashPack

HashPack is trending as it evolves from a standard Hedera wallet into a multi-chain financial hub, recently bolstered by the addition of in-app cross-chain swaps and an upcoming crypto debit card. The community is actively discussing the platform's role as a primary distribution layer for Web3, with significant focus on the recent token listing on Kraken and the impact of email-based wallet creation on user adoption.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as investors capitalize on its status as a low-float, high-volatility play, fueling intense community debate over its potential for a short squeeze versus fears of upcoming dilution. The stock remains a focal point for day traders who are actively tracking breakout levels and monitoring massive borrow fees while debating the sustainability of its recent momentum.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is attracting intense community interest as it pivots into AI data center infrastructure with its new IQ Solid-State Transformer, while the stock grapples with significant post-earnings volatility and broader concerns over solar market demand. Investors remain sharply divided, debating whether the company is a long-term infrastructure play or a speculative trap as they weigh the potential for a rebound against lingering headwinds like tax credit expiration and sector-wide weakness.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending following a strong quarterly earnings report that exceeded estimates, driven by resilient global transaction growth and consumer spending. The community is actively discussing the company's defensive strength, the announcement of a massive new share repurchase program, and its long-term compounding potential as a reliable core portfolio holding.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing significant volatility and community discussion as traders debate the potential for a biotech buyout versus the risks of share dilution or further retracement. Investors are closely monitoring the stock's clinical pipeline, specifically the EB05 asset, while tracking institutional activity and pending conference presentations that could serve as a catalyst for a sustained move.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is surging as the market increasingly views it as a critical infrastructure provider for AI data centers, fueled by an expanded partnership with Oracle and a record-breaking backlog that underscores its ability to meet the urgent power demands of hyperscalers. Investors are actively discussing the stock's parabolic move and the strategic shift toward 'bring-your-own-power' solutions, while some voice concerns over valuation and the potential for equity dilution as the company continues to scale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Markets eased from record highs as investors brace for the Fed rate decision and a crucial wave of Big Tech earnings.&nbsp;</li><li>Brent oil prices surged above $110 amid renewed geopolitical tensions in the Middle East.</li><li>Gold slips to a three-week low, signaling mixed safe-haven positioning.</li></ul>U.S. stock futures retreated from record highs early Tuesday as investors tread carefully ahead of big tech earnings and the Fed's rate decision tomorrow. Geopolitical tensions are also weighing on sentiment. Hopes for a swift resolution to the conflict in the Middle East dimmed after President Trump reportedly expressed skepticism over Iran’s latest peace proposal.Brent crude soared above $110, while gold slipped to a three-week low. As of 4:00 a.m. ET on Tuesday: Nasdaq futures declined 0.5%, S&amp;P 500 futures slipped 0.3%, Russell 2000 futures were down 0.1%, while Dow futures were flat.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved back to ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’, as the tech sector heads into a critical earnings stretch.&nbsp;Trending Stocks To WatchPoet Technologies (POET):&nbsp;Shares were down another 9% in early pre-market trade on news that&nbsp;Marvell Technologies (MRVL) canceled a purchase order connected to its Celestial AI unit.&nbsp;Sellas Lifesciences (SLS):&nbsp;A portfolio manager, Commonwealth Equity Services, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.Nvidia (NVDA) has solidified its status as the most valuable company in the world after hitting a new 52-week high on AI-driven momentum in Monday’s session.&nbsp;Google (GOOGL) has reportedly joined OpenAI and xAI in signing a deal with the U.S. Department of Defense to allow its AI models to be used for classified military work.&nbsp;Oracle (ORCL)&nbsp;is attracting retail interest, driven by buzz around OpenAI's financial health and Oracle’s role as its primary AI backbone.&nbsp;Bed Bath &amp; Beyond (BBBY)&nbsp;is trending on retail radar after reporting its first quarterly revenue growth in five years.&nbsp;Joby Aviation (JOBY):&nbsp;A successful air-taxi demo and a confirmed target for passenger flights in late 2026 are driving this stock 3% higher in early premarket trading.&nbsp;Dynatrace (DT):&nbsp;Activist investor Starboard Value has reportedly built a significant stake in the AI software maker.&nbsp;Intellia Therapeutics (NTLA) and Rocket Labs (RKLB): Cathie Wood’s ARK Invest sold off a portion of its position in Rocket Labs, while adding on to Intellia Therapeutics.&nbsp;Other tickers trending on Stocktwits&nbsp;at the time of writing included Moolec Science SA (MLEC), Canadian Solar Inc (CSIQ), Vir Biotechnology (VIR), and Nio Inc (NIO).Other Catalysts To WatchOn the economic front, traders will be watching the release of the JOLTS Job Openings and CB Consumer Confidence reports this morning.On earnings radar, watch out for quarterly reports from&nbsp;UPS (UPS), General Motors (GM), Commvault Systems (CVLT), JetBlue (JBLU), Sysco (SYY), Spotify (SPOT), Coca-Cola (KO), T-Mobile (TMUS), Kimberly Clark (KMB), Centene (CNC), and Zimmer Biomet (ZBH), before the bell. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Before Fed Call, Earnings Rush: Why POET, MRVL, NVDA, ORCL, SLS Are In Focus

Data from Stocktwits show mixed positioning, with retail turning bullish on SPY but remaining cautious on QQQ.

Equity

Data from Stocktwits show mixed positioning, with retail turning bullish on SPY but remaining cautious on QQQ.


<ul class="summary-bullets"><li>Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares worth $162,730.</li><li>CEO Angelos Stergiou reaffirmed confidence in the trial, saying his conviction in its commercial potential remains “as steadfast today as it was day 1.”</li><li>Sellas is also seeking shareholder approval to expand its equity incentive plan by 20 million shares.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) came into focus on early Tuesday after a portfolio manager, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped over 9% on Monday amid rising hopes around the database-lock milestone for Sellas’ Regal study, which could unlock topline survival data from its lead immunotherapy candidate, GPS.<h2 class="st-heading-2">SLS Draws Fresh Institutional Interest</h2>On Monday, Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares to bring its total holdings to 38,470 shares valued at about $162,730 as of March 31. The boost in stake places Sellas among its other heavyweight healthcare bets, including Eli Lilly, Pfizer, and UnitedHealth.Among its larger portfolio, Sellas sits among its “Magnificent Seven” allocations, including Apple, Nvidia, Microsoft and Amazon.Recently, BlackRock also disclosed ownership of 12.1 million shares, representing 6.8% of Sellas’ shares. Additionally, Dagco raised its position by 78% to 1.03 million shares valued at $4.35 million, making Sellas its second-largest allocation alongside healthcare holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.<h2 class="st-heading-2">CEO Reaffirms Confidence In Sellas’ AML Trial</h2>The increase in stake comes after Sellas CEO Angelos Stergiou said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-jumps-overnight-ceo-backs-aml-drug-20m-share-plan/cZBNIW8Re2E">late Sunday</a> that his confidence in the Regal study’s commercial potential remains unchanged despite the trial remaining blinded. “My conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1,” he said.The ongoing event-driven Phase 3 Regal study is evaluating GPS in patients whose acute myeloid leukemia returned but later entered remission following additional therapy. Final analysis is expected once 80 overall-survival events are recorded, which will trigger database lock, statistical analysis and unblinding. The company previously reported 72 survival events as of Dec. 26, bringing the study closer to the required threshold. Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than initially expected.Beyond the Regal program, Stergiou also said investors should expect updates and topline data readouts from ongoing Phase 2 studies of the company’s CDK9 inhibitor SLS009 this year.&nbsp;<h2 class="st-heading-2">Sellas Proposes 20M Share Reserve Increase&nbsp;</h2>Alongside pipeline progress, Sellas is seeking shareholder approval to expand its share reserve under its 2023 Amended and Restated Equity Incentive Plan by 20 million shares.The company said that only 7,991 shares are available for future awards under the existing plan as of mid-April. The approval would allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect. If rejected, the award would automatically be canceled, and alternative compensation arrangements may be required.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_656e44509c.webp" alt="sls ss.png" width="968" height="147"><figcaption>SLS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/651586857">said</a>, “Far more important than Blackrock or Vanguard is the fact that private wealth and family offices have been actively buying and hoarding shares. Lot of money in that segment. Careful but patient money.”<stembedurl>https://stocktwits.com/OnTheBalance/message/651586857</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Macme/message/651533145">said</a>, “The CEO must have already discussed this 20 million shares with huge partners. It wil pass. Retail is just making noise. The real players like blackrock will surely approve.”<stembedurl>https://stocktwits.com/Macme/message/651533145</stembedurl>SLS stock has surged nearly 250% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-400m-pay-retail-bullish-ahead-of-earnings/cZB8nCTRe5L">Rivian CEO Got $400M While EV Maker Lost $3.6B Last Year — Retail Is Bullish Anyway As Q1 Earnings Near&nbsp;</a>

SLS stock has surged nearly 250% over the past year. (Photo credit: Getty Images)

SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger 

Commonwealth holds Sellas alongside major healthcare names like Eli Lilly, Pfizer, and UnitedHealth.

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>The CEO reaffirmed confidence in the Phase 3 Regal trial evaluating GPS in AML, despite the study remaining blinded.</li><li>Sellas expects clinical updates and Phase 2 readouts for its CDK9 inhibitor, SLS009, this year.</li><li>BlackRock disclosed a 6.8% stake in the cancer drugmaker on Friday.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped over 7% overnight late Sunday after its CEO signaled “steadfast” confidence in the company’s lead acute myeloid leukemia (AML) therapy and urged investors to support a proposal to expand its equity incentive plan by 20 million shares.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> slid about 15% last week, logging its worst weekly performance in nearly four months.<h2 class="st-heading-2">Sellas CEO Signals ‘Steadfast’ Confidence In Regal Trial</h2>CEO Angelos Stergiou said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7454295346865729537/">LinkedIn post</a> late Sunday that his conviction in the Regal trial’s commercial prospects remains unchanged despite the study still being blinded.“My conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1,” he said. The ongoing event-driven Phase 3 Regal study is evaluating GPS in patients whose AML returned but later entered remission after additional therapy. Final analysis of the trial is expected once 80 overall-survival events are recorded, which triggers database lock, statistical analysis and unblinding.Sellas previously said 72 survival events had been recorded as of Dec. 26, bringing the study closer to the milestone required for topline analysis. Stergiou also said that slower accumulation of survival events in cancer studies can sometimes indicate that patients are living longer than initially expected.“While strict trial blinding prevents any definitive guarantees before unblinding, my belief in the asset—and the prolonged survival trend we are observing—has not diminished in the slightest,” Stergious said in the post.GPS targets Wilms Tumor-1 (WT1), a protein commonly found in many cancers and ranked by the National Cancer Institute as a leading immunotherapy target. The treatment uses engineered fragments of WT1 to activate key immune cells that help destroy cancer cells.<h2 class="st-heading-2">SLS009 Updates Expected This Year</h2>Stergiou also pointed to 2026 as an important year for&nbsp;the development of the CDK9 inhibitor SLS009. “Investors should look for clinical updates and top-line data readouts from our ongoing Phase 2 studies this calendar year,” he said.Recent lab findings presented ahead of a key cancer summit showed that the therapy helped trigger the natural self-destruction process in leukemia cells while reducing proteins that cancer cells rely on to survive. The drug also remained active in hard-to-treat forms of AML linked to ASXL1 and TP53 mutations, which are typically associated with poorer outcomes.Investor expectations had been building around potential updates from SLS009 last week, leaving the stock in&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-slips-after-hours-cancer-pipeline-silence-china-licensing-arbitration/cZBBanERI6u">wait-and-watch mode</a> after the anticipated pipeline developments did not immediately land at a cancer summit.<h2 class="st-heading-2">Sellas Seeks Approval To Add 20M Shares</h2>Alongside pipeline updates, Stergiou sought approval to expand the share reserve under its 2023 Amended and Restated Equity Incentive Plan by 20 million shares. The amendment would add more shares to the company’s stock-based compensation pool after Sellas disclosed that only 7,991 shares remained available for future awards under its existing plan as of mid-April.Approval of the new proposal would allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect, while rejection would automatically cancel the award and could require the company to consider alternative compensation arrangements.As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.&nbsp;<h2 class="st-heading-2">Institutional Participation Builds Ahead Of Catalysts</h2>Institutional participation in the stock has remained active ahead of expected clinical milestones. On Friday, BlackRock disclosed a stake of about 12.1 million shares, representing 6.8% of Sellas’ outstanding common stock.Data compiled by Quiver Quantitative showed last week that Dagco&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-premarket-dagco-raises-stake-ahead-of-aacr-leukemia-data/cZBIfhbRICL">increased its stake</a> by 78%, bringing its total holdings to 1.03 million shares valued at about $4.35 million as of March 31. The position now represents Dagco’s second-largest disclosed allocation at 1.01% of its portfolio, placing Sellas among its healthcare bets alongside larger pharma companies such as Merck, Thermo Fisher Scientific, and Johnson &amp; Johnson.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has jumped to ‘bullish’ from ‘bearish’ levels over the past week amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_9245b89031.webp" alt="sls ss.png" width="973" height="142"><figcaption>SLS sentiment and message volume as of April 26 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/vlucky16/message/651465697">said</a>, “Sterge doing what's best for patients and stockholders. Just sit back and watch warrants and loose shares get gobbled up. At some point Game Over for shorts!!!”<stembedurl>https://stocktwits.com/vlucky16/message/651465697</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/PejalPapa/message/651464553">said</a>, “I would at least like to see an IDMC report with event no and a signal to keep going. Not sure how his posts like that are building a shareholder value with so much uncertainty on the direction of the trial.”<stembedurl>https://stocktwits.com/PejalPapa/message/651464553</stembedurl>SLS stock has surged 233% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jpmorgan-sees-tokenized-etfs-as-the-next-big-thing/cZBkpZpRe23">JPMorgan Sees Tokenized ETFs As The Next Big Thing, But Adoption Timeline Is Still Unclear</a>

SLS stock has surged 233% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps Overnight: CEO Doubles Down On ‘Steadfast’ Confidence In AML Drug And Pushes For 20M Share Plan Approval 

Sellas is seeking approval to add 20 million shares to its equity plan after nearly exhausting its current pool, with only 7,991 shares remaining.

SELLAS Life Sciences Group (NASDAQ:SLS)  Shares Down 8.1%   - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% - Here's Why...

<ul class="summary-bullets"><li>Anticipated updates on the company’s leukemia drug SLS009 did not land, dampening near-term catalyst momentum.</li><li>Earlier studies showed SLS009 triggered leukemia cell death and remained active in difficult-to-treat AML cases with ASXL1 and TP53 mutations.</li><li>Attention also remains on the Phase 3 Regal trial, where survival events are approaching the threshold required to begin topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) slipped nearly 1% in after-hours trading on Tuesday as investors remained in wait-and-watch mode after expected cancer-pipeline updates failed to land, turning focus toward a pending China licensing arbitration decision tied to Phase 3 milestone payments for its lead acute myeloid leukemia (AML) program.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> ended the regular session about 1% higher at $5.03.<h2 class="st-heading-2">SLS009 Update Fails To Land</h2>Investor expectations had been building around potential updates on the company’s leukemia drug SLS009, which earlier studies showed could help trigger cancer cell death while blocking survival signals that leukemia cells rely on. The treatment also showed activity in hard-to-treat AML cases with ASXL1 and TP53 mutations, genetic changes often linked to poorer outcomes.SLS shares also drew investor attention on Tuesday after U.S. investment manager Dagco&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-premarket-dagco-raises-stake-ahead-of-aacr-leukemia-data/cZBIfhbRICL">increased</a> its stake in the company by 78% ahead of anticipated catalysts in the company's leukemia pipeline.<h2 class="st-heading-2">China Milestone Payment Dispute In Focus</h2>Focus has now turned to an arbitration proceeding involving Sellas and its Chinese partner 3D Medicines covering development and commercialization rights for 3D189, the regional version of the company’s immunotherapy candidate Galinpepimut-S (GPS), as well as 3D059, the regional version of SLS009.The arbitration includes disputes over milestone payments tied to the initiation of Phase 3 clinical development for 3D189, and whether the regional partner maintained sufficient expertise and resources to meet its obligations under the licensing agreement.The tribunal directed both parties to submit final closing submissions by April 21, moving the case into its decision phase.&nbsp;Sellas previously said that it received $10.5 million in upfront and milestone payments under its Greater China agreement with 3D Medicines, while up to $191.5 million in additional development, regulatory and commercial milestone payments remain possible under the licensing deal, excluding potential future royalties.<h2 class="st-heading-2">Regal Trial Readout Watch Builds</h2>Beyond the arbitration process, investor attention continues to center on the company’s ongoing Phase 3 Regal trial evaluating GPS as a maintenance therapy for AML patients whose disease returned but later entered remission after additional therapy.Sellas previously said 72 overall survival events had been recorded as of late December, approaching the 80-event threshold required to begin topline analysis. CEO Angelos Stergiou has said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than expected compared with historical assumptions.However, with no meaningful update emerging from the summit session as expected, attention appears to shift toward another near-term catalyst for the drugmaker.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has improved to ‘bullish’ from ‘neutral’ levels a day ago amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_8e6702e3ff.webp" alt="sls ss.png" width="968" height="144"><figcaption>SLS sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Arnold_Stonkinator/message/650962118">noted</a> that while the SLS009 poster presentation drew attention, the absence of a formal company update or management communication on National AML Awareness Day stood out.<stembedurl>https://stocktwits.com/Arnold_Stonkinator/message/650962118</stembedurl>Another user expressed frustration, saying, “If they are going to go silent then do that and don't go to conferences, don't tweet, stop communicating completely.&nbsp; It just gives Shorts something else to see. Sterg we don't want to hear from you unless it is a BO.”<stembedurl>https://stocktwits.com/StandingByWaiting/message/650959906</stembedurl>SLS stock has surged 290% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-pares-losses-after-hours-citi-amazon-glp1-caveat/cZBB74RRI6q">HIMS Stock Pares Losses After-Hours: Citi Flags ‘Big Caveat’ In Amazon’s GLP-1 Push That Limits Risk To Hims Model</a>

SLS stock has surged 290% over the past year.  (Photo credit: Getty Images)

SLS Stock Slips After-Hours As Cancer Pipeline Silence Frustrates Retail — China Licensing Fight Now In Spotlight

SLS Stock - Investor focus has shifted to an ongoing arbitration with 3D Medicines over Phase 3 milestone payments tied to the Greater China rights for GPS and SLS009.

Investor focus has shifted to an ongoing arbitration with 3D Medicines over Phase 3 milestone payments tied to the Greater China rights for GPS and SLS009.

<ul class="summary-bullets"><li>Dagco added 451,240 shares, making Sellas its second-largest holding at 1.01% of portfolio weight.</li><li>The stake increase comes ahead of AACR presentation of preclinical data on SLS009, Sellas’ CDK9 inhibitor targeting acute myeloid leukemia (AML).</li><li>Investor focus remains centered on the Phase 3 Regal trial of GPS, with 72 of 80 required survival events recorded as of Dec. 26, moving the study closer to topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped 5% in premarket trading on Monday after U.S. investment manager Dagco increased its stake by 78% ahead of a major AACR leukemia data catalyst and the closely watched Regal survival trigger.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> snapped four sessions of gains on Monday to end over 4% lower at $4.99.<h2 class="st-heading-2">Dagco Loads Up Ahead Of SLS009 AACR Data</h2>Data compiled by Quiver Quantitative showed that Dagco added 451,240 shares on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million as of March 31. The position now represents its second biggest holding at 1.01% of Dagco’s disclosed portfolio, placing Sellas among its healthcare bets alongside larger pharma holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.The stake increase comes just as Sellas prepares to present new preclinical findings on SLS009, its CDK9 inhibitor for acute myeloid leukemia (AML), during a poster session at AACR in San Diego on Tuesday.According to the company, lab studies showed that SLS009 triggered leukemia-cell death by increasing activity of caspase-3, a protein involved in the body’s natural cell-death process, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also showed stronger potency with repeated exposure, with early biological effects appearing within hours and becoming more pronounced over 24 hours.Notably, SLS009 remained active in AML carrying ASXL1 and TP53 mutations, which are genetic subtypes associated with treatment resistance and poorer outcomes.&nbsp;<h2 class="st-heading-2">Regal Survival Countdown In Focus</h2>While the AACR presentation represents a near-term catalyst, investor attention remains firmly centered on the company’s ongoing Phase 3 Regal trial evaluating GPS, an immunotherapy targeting the Wilms Tumor-1 antigen, as a maintenance treatment for AML patients whose disease returned but later entered remission after additional therapy.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said 72 events had been logged as of Dec. 26, bringing the trial closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than expected compared with historical assumptions. Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, trial unblinding and disclosure of topline results.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_226ba9d4c9.webp" alt="sls ss.png" width="973" height="147"><figcaption>SLS sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/yG19/message/650823713">noted</a> Diagco’s stake and said, “It's likely clearly see the asymmetric upside with the margin of safety of no REGAL downside.”<stembedurl>https://stocktwits.com/yG19/message/650823713</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/vlucky16/message/650846855">said</a>, “Can't wait to get update on 009, since GPS has been put on hold for an 80th event that might happen from old age.”<stembedurl>https://stocktwits.com/vlucky16/message/650846855</stembedurl>SLS stock has surged over 280% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-premarket-ross-gerber-brand-backlash-ai-pivot-earnings-check/cZBIOqKRICO">Tesla Stock Rises Premarket: Investor Ross Gerber Says ‘People Just Hate The Brand Now’ As AI Pivot Faces Earnings Reality Check</a>

SLS Stock Jumps Premarket: US Investor Dagco Boosts Stake By 78% Ahead Of Fresh Cancer Drug Data Reveal 

Sellas is now Dagco’s second-largest disclosed holding, putting the small-cap leukemia biotech alongside pharma giants like Merck and Johnson & Johnson.

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

While SLS stock has surged nearly 300% over the past year, ATNM has climbed 7% over the same period. (Photo credit: Getty Images)

SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal?

Analyst estimates suggest ATNM carries the wider valuation runway, with 342% upside versus about 66% for SLS.

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

What do you expect the Fed to decide at its FOMC meeting Wednesday?

Stocktwits

Stocktwits Polls

Investors are closely tracking the Phase 3 trial milestones and awaiting unblinded data regarding survival events for AML patients.

Significant community debate persists over the impact of ongoing share dilution, warrant offerings, and proposed executive compensation.

Retail investors and bears remain deadlocked, trading insults over high short volumes and conflicting price target predictions.

Speculation runs rampant about a potential buyout as market participants analyze historical sector deal activity and trial potential.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLSSELLAS Life Sciences Group Inc